Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 8:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Patupilone; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 4
States / cities: Louisville, Kentucky • Columbia, Missouri • Pittsburgh, Pennsylvania + 1 more

Conditions: Healthy
Interventions: JNJ-39439335 10 mg, JNJ-39439335 25 mg, JNJ-39439335 50 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 20 Years to 55 Years · Male only
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Cypress, California

Conditions: Advanced or Metastatic Breast Cancer
Interventions: AND019 PO QD; Drug
Lead sponsor: Kind Pharmaceuticals LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Dental Caries
Interventions: C16G2; Drug
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Kalispell, Montana • Salt Lake City, Utah

Conditions: Lactation, Weight Loss
Interventions: Injected GLP-1 Receptor Agonists and Dual Agonists; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Oncology Patients, Tumors
Interventions: AMG 820; Drug
Lead sponsor: AmMax Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Greenville, South Carolina • San Antonio, Texas

Conditions: Follicular Lymphoma (FL)
Interventions: Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prenisolone; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 733 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 9
States / cities: Plantation, Florida • Noblesville, Indiana • Wichita, Kansas + 6 more

Conditions: Pancreatic Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
Interventions: BTP-114; Drug
Lead sponsor: Placon Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: Sarasota, Florida • Boston, Massachusetts • St Louis, Missouri + 4 more

Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
Interventions: Capivasertib, Fulvestrant, Palbociclib, Ribociclib, Abemaciclib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 893 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 40
States / cities: Tucson, Arizona • Fountain Valley, California • Glendale, California + 35 more

Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Interventions: oral rigosertib, Azacitidine; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 12
States / cities: Gilbert, Arizona • Duarte, California • Rancho Mirage, California + 9 more

Conditions: Food Allergy
Interventions: Omalizumab; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 1 Year to 30 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia
Interventions: AMG 176, Azacitidine, Itraconazole; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 10
States / cities: Duarte, California • Sacramento, California • Aurora, Colorado + 7 more

Conditions: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer
Interventions: JANX007, Darolutamide; Biological · Drug
Lead sponsor: Janux Therapeutics; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more

Conditions: Healthy Adult Participants
Interventions: ARN-75039 oral capsules, Placebo; Drug
Lead sponsor: Arisan Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Hepatitis D, Chronic
Interventions: JNJ-73763989, Placebo, Entecavir (ETV) monohydrate, Tenofovir disoproxil, Tenofovir alafenamide (TAF); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: Redwood City, California • Boston, Massachusetts

Conditions: Autism Spectrum Disorder, Obesity
Interventions: Glucagon-like peptide-1 receptor agonist：Semaglutide, Lifestyle Management (LSM) Counseling; Drug · Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 12 Years to 18 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Lung Cancer
Interventions: ZD6474, Carboplatin, Paclitaxel; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Health Information Technology, Health Information Exchange, Virtual Health Record, Health Care Utilization
Interventions: Virtual Health Record (VHR); Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 218,766 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 3
States / cities: Buffalo, New York • New York, New York • Rochester, New York

Conditions: Acute Leukemia
Interventions: Exercise; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: cisplatin, everolimus, gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy; Drug · Genetic · Other + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Pain, Inflammation
Interventions: Restorative-Flow Yoga; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 60 Years and older · Female only
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Ithaca, New York

Conditions: Healthy Volunteers
Interventions: BGB-43395; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Bladder Pain and Discomfort, Urinary Urgency and Frequency, Bothersome Symptoms
Interventions: Pain sensitivity testing, Urodynamic testing; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hodgkin's Disease, Lymphoma, Non-Hodgkin
Interventions: Y-90 Humanized Anti-Tac, Calcium-DTPA; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung Cancer

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants

A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

Phase 2, Open-Label Study for Safety, Microbiology and PK of Single or Multiple Oral C16G2 Gel Doses

Effects of GLP-1 RAs on Human Lactation Outcomes

A Study of AMG 820 in Subjects With Advanced Solid Tumors

A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine

Oral Food Challenge After One to Two Doses of Omalizumab Treatment for Food Allergy

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects

A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus

Semaglutide in Youth With Autism Spectrum Disorder

Phase II Study of ZD6474 in Advanced NSCLC

Assessing the Impact of Health Information Exchange (HIE) on Healthcare Utilization

Exercise and Quality of Life in Leukemia Patients

Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors

Flow-Restorative Yoga to Decrease Pain and Inflammation

A Study of Different Forms of BGB-43395 and Food Effect in Healthy Participants

Sensory Sensitivity and Urinary Symptoms in the Female Population

Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia